Structural characterization of protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus
Journal Article
·
· Nature Communications
more »
- Univ. of Georgia, Athens, GA (United States)
- Univ. of Maryland, Baltimore, MD (United States). School of Medicine
- Centers for Disease Control and Prevention (CDC), Atlanta, GA (United States); Univ. of California, Riverside, CA (United States)
- Centers for Disease Control and Prevention (CDC), Atlanta, GA (United States)
- Univ. of California, Riverside, CA (United States)
- US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD (United States)
- Univ. of Georgia, Athens, GA (United States). College of Veterinary Medicine
- Acibadem University Atakent Hospital, Istanbul (Turkey)
- Karadeniz Technical University School of Medicine, Trabzon (Turkey)
- Bitlis State Hospital (Turkey)
- Univ. of Georgia, Athens, GA (United States); Centers for Disease Control and Prevention (CDC), Atlanta, GA (United States)
- Univ. of California, Riverside, CA (United States); United States Military Academy, West Point, NY (United States)
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) causes a life-threatening disease with up to a 40% mortality rate. With no approved medical countermeasures, CCHFV is considered a public health priority agent. The non-neutralizing mouse monoclonal antibody (mAb) 13G8 targets CCHFV glycoprotein GP38 and protects mice from lethal CCHFV challenge when administered prophylactically or therapeutically. Here, we reveal the structures of GP38 bound with a human chimeric 13G8 mAb and a newly isolated CC5-17 mAb from a human survivor. These mAbs bind overlapping epitopes with a shifted angle. The broad-spectrum potential of c13G8 and CC5-17 and the practicality of using them against Aigai virus, a closely related nairovirus were examined. Binding studies demonstrate that the presence of non-conserved amino acids in Aigai virus corresponding region prevent CCHFV mAbs from binding Aigai virus GP38. This information, coupled with in vivo efficacy, paves the way for future mAb therapeutics effective against a wide swath of CCHFV strains.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- USDOE Office of Science (SC), Biological and Environmental Research (BER)
- Grant/Contract Number:
- AC02-06CH11357
- OSTI ID:
- 2423642
- Journal Information:
- Nature Communications, Journal Name: Nature Communications Journal Issue: 1 Vol. 13; ISSN 2041-1723
- Publisher:
- Nature Publishing GroupCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38
Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38
Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus
Journal Article
·
Mon Mar 30 20:00:00 EDT 2020
· Journal of Virology
·
OSTI ID:1839757
Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38
Journal Article
·
Fri Jul 12 20:00:00 EDT 2024
· Cell Reports
·
OSTI ID:2470075
Molecular Insights into Crimean-Congo Hemorrhagic Fever Virus
Journal Article
·
Wed Apr 20 20:00:00 EDT 2016
· Viruses
·
OSTI ID:1258588